X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Alivexis grants Melodia worldwide rights to develop, manufacture, and commercialize MDI-0151 for the treatment of inflammatory diseases.
Lead Product(s): MDI-0151
Therapeutic Area: Immunology Product Name: MDI-0151
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Melodia Therapeutics
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 21, 2024
Details:
Modulus will use the proceeds to further its portfolio of R&D programs driven by its proprietary computational drug discovery platform and globally networked operational model including lead asset MOD-A.
Lead Product(s): MOD-A
Therapeutic Area: Immunology Product Name: MOD-A
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Green Coinvest Investment Limited
Deal Size: $20.4 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 01, 2022
Details:
Modulus will use the proceeds to further its unique small-molecule lead programs in oncology and inflammatory / immune disorders and expand its portfolio of early programs and collaborations including those with its strategic partner, PeptiDream, Inc.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SBI Investments
Deal Size: $25.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
